{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:43:08Z","timestamp":1774474988558,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T00:00:00Z","timestamp":1256342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00120-009-2141-y","type":"journal-article","created":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T19:30:20Z","timestamp":1256239820000},"page":"1365-1377","source":"Crossref","is-referenced-by-count":9,"title":["Medikament\u00f6se Therapie der benignen Prostatahyperplasie","Pharmacological treatment of benign prostatic hyperplasia"],"prefix":"10.1007","volume":"48","author":[{"given":"M.","family":"Oelke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.R.W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,24]]},"reference":[{"key":"2141_CR1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/bmj.308.6934.929","volume":"308","author":"Abrams","year":"1994","unstructured":"Abrams P (1994) New words for old: lower urinary tract symptoms for \u201eprostatism\u201c. BMJ 308:929\u2013930","journal-title":"BMJ"},{"key":"2141_CR2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"2141_CR3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","volume":"175","author":"Abrams","year":"2006","unstructured":"Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175:999\u20131004","journal-title":"J Urol"},{"key":"2141_CR4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","volume":"44","author":"Barkin","year":"2003","unstructured":"Barkin J, Guimaraes M, Jacobi G et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5\u03b1-reductase inhibitor dutasteride. Eur Urol 44:461\u2013466","journal-title":"Eur Urol"},{"key":"2141_CR5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1159\/000052527","volume":"39","author":"Berges","year":"2001","unstructured":"Berges RR, Pientka L, H\u00f6fner K et al (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682\u2013687","journal-title":"Eur Urol"},{"key":"2141_CR6","first-page":"in","volume":"2009","author":"Berges","year":"2009","unstructured":"Berges R, Dreikorn K, H\u00f6fner K et al (2009) Leitlinien der Deutschen Urologen zur Diagnostik und Differenzialdiagnostik des benignen Prostatasyndroms (BPS). Urologe A 2009: in Druck","journal-title":"Urologe A"},{"key":"2141_CR7","first-page":"in","volume":"A","author":"Berges","year":"2009","unstructured":"Berges R, Dreikorn K, H\u00f6fner K et al (2009) Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms (BPS). Urologe A: in Druck","journal-title":"Urologe"},{"key":"2141_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474\u2013479","journal-title":"J Urol"},{"key":"2141_CR9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1464-410X.1994.tb16586.x","volume":"74","author":"Chancellor","year":"1994","unstructured":"Chancellor MB, Rivas DA, Keeley FX et al (1994) Similarity of the American Urological Association Symptom Index among men with benign prostatic hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br J Urol 74:200\u2013203","journal-title":"Br J Urol"},{"key":"2141_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pros.2990150508","volume":"2","author":"Hald","year":"1989","unstructured":"Hald T (1989) Urodynamics in benign prostatic hyperplasia. A survey. Prostate Suppl 2:69\u201377","journal-title":"Prostate Suppl"},{"key":"2141_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.eururo.2006.05.001","volume":"50","author":"Hutchison","year":"2006","unstructured":"Hutchison A, Farmer R, Chapple C et al (2006) Characteristics of patients presenting with LUTS\/BPH in six European countries. Eur Urol 50:555\u2013562","journal-title":"Eur Urol"},{"key":"2141_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eursup.2003.09.002","volume":"2","author":"Jimenez-Cruz","year":"2003","unstructured":"Jimenez-Cruz F (2003) Identifying the patients at risk for disease progression. Eur Urol Suppl 2:6\u201312","journal-title":"Eur Urol Suppl"},{"key":"2141_CR13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 296:2319\u20132328","journal-title":"JAMA"},{"key":"2141_CR14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","volume":"94","author":"Lee","year":"2004","unstructured":"Lee JY, Kim HW, Lee SJ et al (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive detrusor. BJU Int 94:817\u2013820","journal-title":"BJU Int"},{"key":"2141_CR15","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of Doxazosin, Finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398","journal-title":"N Engl J Med"},{"key":"2141_CR16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","volume":"168","author":"Michel","year":"2002","unstructured":"Michel MC, Schneider T, Krege S, Goepel M (2002) Does gender or age affect the efficacy and safety of tolterodine? J Urol 168:1027\u20131031","journal-title":"J Urol"},{"key":"2141_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00120-002-0236-9","volume":"41","author":"Oelke","year":"2002","unstructured":"Oelke M, H\u00f6fner K, Berges RR, Jonas U (2002) Medikament\u00f6se Therapie des benignen Prostatasyndroms mit \u03b11-Rezeptorblockern. Urologe A 41:425\u2013441","journal-title":"Urologe A"},{"key":"2141_CR18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","volume":"54","author":"Oelke","year":"2008","unstructured":"Oelke M, Baard J, Wijkstra H et al (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54:419\u2013426","journal-title":"Eur Urol"},{"key":"2141_CR19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","volume":"157","author":"Peters","year":"1997","unstructured":"Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society \u201eBenign Prostatic Hyperplasia\u201c Study: the bothersomeness of urinary symptoms. J Urol 157:885\u2013889","journal-title":"J Urol"},{"key":"2141_CR20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","volume":"179","author":"Roehrborn","year":"2008","unstructured":"Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the ComBAT study. J Urol 179:616\u2013621","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-009-2141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-009-2141-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-009-2141-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:48:07Z","timestamp":1558626487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-009-2141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,24]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["2141"],"URL":"https:\/\/doi.org\/10.1007\/s00120-009-2141-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,24]]}}}